These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 18232722)

  • 1. Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment.
    Janicak PG; O'Reardon JP; Sampson SM; Husain MM; Lisanby SH; Rado JT; Heart KL; Demitrack MA
    J Clin Psychiatry; 2008 Feb; 69(2):222-32. PubMed ID: 18232722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcranial magnetic stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial.
    Avery DH; Isenberg KE; Sampson SM; Janicak PG; Lisanby SH; Maixner DF; Loo C; Thase ME; Demitrack MA; George MS
    J Clin Psychiatry; 2008 Mar; 69(3):441-51. PubMed ID: 18294022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial.
    O'Reardon JP; Solvason HB; Janicak PG; Sampson S; Isenberg KE; Nahas Z; McDonald WM; Avery D; Fitzgerald PB; Loo C; Demitrack MA; George MS; Sackeim HA
    Biol Psychiatry; 2007 Dec; 62(11):1208-16. PubMed ID: 17573044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of transcranial magnetic stimulation in unipolar depression: A systematic review and meta-analysis of randomized-controlled trials.
    Wang WL; Wang SY; Hung HY; Chen MH; Juan CH; Li CT
    J Affect Disord; 2022 Mar; 301():400-425. PubMed ID: 35032510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period.
    Dunner DL; Aaronson ST; Sackeim HA; Janicak PG; Carpenter LL; Boyadjis T; Brock DG; Bonneh-Barkay D; Cook IA; Lanocha K; Solvason HB; Demitrack MA
    J Clin Psychiatry; 2014 Dec; 75(12):1394-401. PubMed ID: 25271871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center.
    Connolly KR; Helmer A; Cristancho MA; Cristancho P; O'Reardon JP
    J Clin Psychiatry; 2012 Apr; 73(4):e567-73. PubMed ID: 22579164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in quality of life with left prefrontal transcranial magnetic stimulation in patients with pharmacoresistant major depression: acute and six month outcomes.
    Solvason HB; Husain M; Fitzgerald PB; Rosenquist P; McCall WV; Kimball J; Gilmer W; Demitrack MA; Lisanby SH
    Brain Stimul; 2014; 7(2):219-25. PubMed ID: 24332384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trial of transcranial magnetic stimulation in pregnant women with major depressive disorder.
    Kim DR; Wang E; McGeehan B; Snell J; Ewing G; Iannelli C; O'Reardon JP; Sammel MD; Epperson CN
    Brain Stimul; 2019; 12(1):96-102. PubMed ID: 30249416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression.
    Leuchter AF; Cook IA; Feifel D; Goethe JW; Husain M; Carpenter LL; Thase ME; Krystal AD; Philip NS; Bhati MT; Burke WJ; Howland RH; Sheline YI; Aaronson ST; Iosifescu DV; O'Reardon JP; Gilmer WS; Jain R; Burgoyne KS; Phillips B; Manberg PJ; Massaro J; Hunter AM; Lisanby SH; George MS
    Brain Stimul; 2015; 8(4):787-94. PubMed ID: 26143022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial.
    Lisanby SH; Husain MM; Rosenquist PB; Maixner D; Gutierrez R; Krystal A; Gilmer W; Marangell LB; Aaronson S; Daskalakis ZJ; Canterbury R; Richelson E; Sackeim HA; George MS
    Neuropsychopharmacology; 2009 Jan; 34(2):522-34. PubMed ID: 18704101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study.
    Janicak PG; Nahas Z; Lisanby SH; Solvason HB; Sampson SM; McDonald WM; Marangell LB; Rosenquist P; McCall WV; Kimball J; O'Reardon JP; Loo C; Husain MH; Krystal A; Gilmer W; Dowd SM; Demitrack MA; Schatzberg AF
    Brain Stimul; 2010 Oct; 3(4):187-99. PubMed ID: 20965447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. H-coil repetitive transcranial magnetic stimulation for treatment resistant major depressive disorder: An 18-week continuation safety and feasibility study.
    Harel EV; Rabany L; Deutsch L; Bloch Y; Zangen A; Levkovitz Y
    World J Biol Psychiatry; 2014 May; 15(4):298-306. PubMed ID: 22313023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A two-site pilot randomized 3 day trial of high dose left prefrontal repetitive transcranial magnetic stimulation (rTMS) for suicidal inpatients.
    George MS; Raman R; Benedek DM; Pelic CG; Grammer GG; Stokes KT; Schmidt M; Spiegel C; Dealmeida N; Beaver KL; Borckardt JJ; Sun X; Jain S; Stein MB
    Brain Stimul; 2014; 7(3):421-31. PubMed ID: 24731434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can Medication Free, Treatment-Resistant, Depressed Patients Who Initially Respond to TMS Be Maintained Off Medications? A Prospective, 12-Month Multisite Randomized Pilot Study.
    Philip NS; Dunner DL; Dowd SM; Aaronson ST; Brock DG; Carpenter LL; Demitrack MA; Hovav S; Janicak PG; George MS
    Brain Stimul; 2016; 9(2):251-7. PubMed ID: 26708778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcranial magnetic stimulation (TMS) in the treatment of attention-deficit/hyperactivity disorder in adolescents and young adults: a pilot study.
    Weaver L; Rostain AL; Mace W; Akhtar U; Moss E; O'Reardon JP
    J ECT; 2012 Jun; 28(2):98-103. PubMed ID: 22551775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial.
    George MS; Lisanby SH; Avery D; McDonald WM; Durkalski V; Pavlicova M; Anderson B; Nahas Z; Bulow P; Zarkowski P; Holtzheimer PE; Schwartz T; Sackeim HA
    Arch Gen Psychiatry; 2010 May; 67(5):507-16. PubMed ID: 20439832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No change in neuropsychological functioning after receiving repetitive transcranial magnetic stimulation treatment for major depression.
    Wajdik C; Claypoole KH; Fawaz W; Holtzheimer PE; Neumaier J; Dunner DL; Haynor DR; Roy-Byrne P; Avery DH
    J ECT; 2014 Dec; 30(4):320-4. PubMed ID: 24625717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral activation therapy during transcranial magnetic stimulation for major depressive disorder.
    Russo GB; Tirrell E; Busch A; Carpenter LL
    J Affect Disord; 2018 Aug; 236():101-104. PubMed ID: 29723763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the Effects of Repetitive Transcranial Magnetic Stimulation on Cognition in Major Depressive Disorder Using Computerized Cognitive Testing.
    Galletly C; Gill S; Rigby A; Carnell BL; Clarke P
    J ECT; 2016 Sep; 32(3):169-73. PubMed ID: 26934275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a 10-day trigeminal nerve stimulation (TNS) protocol for treating major depressive disorder: a phase II, sham-controlled, randomized clinical trial.
    Shiozawa P; da Silva ME; Netto GT; Taiar I; Cordeiro Q
    Epilepsy Behav; 2015 Mar; 44():23-6. PubMed ID: 25597529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.